• To assess the cost-effectiveness of mirabegron compared with antimuscarinic agents: tolterodine, solifenacin and fesoterodine, in patients with OAB symptoms from a Spanish National Health Service (NHS) perspective.
OBJECTIVES
• A Markov model was developed to simulate the course and disease management, as well as the adverse effects of treatment, in OAB patients over a period of 5 years ( Figure 1 ).
• The main assumptions of the Markov model are presented in Table 1. • Direct health care costs (€, cost year 2015) included drug acquisition, primary care physician and specialist physician visits, incontinence pads, surgical procedures, adverse effects of treatment and botox injections were obtained from Spanish sources 7 .
• Relative effectiveness and tolerability estimates of mirabegron 50mg vs tolterodine, fesoterodine, solifenacin 5 and 10mg were obtained from the SCORPIO clinical trial 8 and from a network meta-analysis 9 , using a calibration method 10 .
• Effectiveness was measured as quality-adjusted life-years (QALYs) gained.
• Other model inputs were derived from the literature or clinical expert opinion.
• Deterministic and probabilistic sensitivity analyses (SA) were undertaken.
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• Mirabegron 50mg/day was associated with a gain of 0.01259 QALYs at an additional cost of €194 per patient vs tolterodine 4mg.The resulting incremental cost effectiveness ratio (ICER) was €15,388/QALY gained ( Table 2 ). The probability of mirabegron 50 mg/day being cost-effective relative to tolterodine 4mg/day was 81.9% at a willingness to pay threshold of € 30,000/QALY (Figure 2 , Table 3 ).
• Incremental cost-effectiveness ratios of mirabegron 50mg/day versus solifenacin 5 and 10 mg/day were €2,536 and €4,837 per QALY gained, respectively ( Table 2 ). The probability of cost effectiveness for mirabegron 50mg/day was 90.0% and 90.5% versus solifenacin 5 and 10 mg/day respectively ( Figure 2 , Table 3 ).
• Mirabegron 50mg/day was the dominant treatment (more effective with lower costs) versus fesoterodine 4 and 8 mg/day (Table 2 ) with a probability of costeffectiveness of 93.8% and 93.1%, respectively. (Table 3 ). • Mirabegron 50 mg/day is a cost-effective treatment compared with antimuscarinic agents and dominant versus fesoterodine 4 and 8 mg/day in OAB patients from Spanish NHS perspective.
ECONOMIC EVALUATION OF MIRABEGRON VERSUS ANTIMUSCARINIC TREATMENTS IN PATIENTS WITH OVERACTIVE BLADDER FROM THE PESPECTIVE OF THE SPANISH NATIONAL HEALTH SERVICE
(1 Table 3 . Cost-effectiveness probability for a threshold of <30,000/QALY gained.
• Overactive bladder (OAB) is a symptom-defined condition characterized by urinary urgency, usually accompanied by urinary frequency and nocturia, and sometimes by urgency incontinence 1 .
• It is estimated that in Spain OAB prevalence is 21.5% for people over 40 years 2 .
• OAB markedly affects quality of life, with significant detrimental effects on daily activities, sleep, mental health, travel, work and personal relationships 3-5 .
• Mirabegron is a novel β 3 -adrenergic agonist that has been shown in Phase III clinical trials to significantly improve OAB symptoms and to have good tolerability 6 .
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vs tolterodine 4 mg. 
